Articles and White Papers

You might also be interested in our Related Links page.

Krohn, T. and Crist, B. Clinical Open Innovation: Reinventing Invention through an Open Clinical Intelligence Network. January 2012.

The pharmaceutical industry is ripe with innovation opportunities. To find it, all the industry has to do is look outside its own walls. In recent years, a dramatic shift in the availability and use of information has occurred.  People everywhere have become empowered by digital knowledge and are collaborating to utilize information in innovative ways. Much of this shift, however, hasn't been applied to the invention processes in life sciences, especially in contrast to other industries. Here is where the opportunity and our vision for Clinical Open Innovation lies.

Read the full paper.

Lilly MDR-TB Partnership. Tuberculosis and Multidrug-Resistant Tuberculosis: An Overview. Geneva, Switzerland. July 2011.

The devastation of TB is a stark and inescapable reality for many individuals, families and communities around the globe. The Lilly MDR-TB Partnership, founded in 2003, works to share knowledge, expertise and research in the quest to contain and conquer MDR-TB, a disease that disproportionately affects impoverished populations. This overview provides background information about MDR-TB and the Lilly MDR-TB Partnership.

This overview provides background information about MDR-TB and the Lilly MDR-TB Partnership. 

Munos, B.H. and Chin, W.W. How to Revive Breakthrough Innovation in the Pharmaceutical Industry.

Available through www.ScienceTranslationalMedicine.org, 29 June 2011. Vol 3, Issue 89 89cm16.

Over the past 20 years, pharmaceutical companies have implemented conservative management practices to improve the predictability of therapeutics discovery and success rates of drug candidates. This approach has often yielded compounds that are only marginally better than existing therapies, yet require larger, longer, and more complex trials. To fund them, companies have shifted resources away from drug discovery to late clinical development; this has hurt innovation and amplified the crisis brought by the expiration of patients on many best-selling drugs. Here, we argue that more breakthrough therapeutics will reach patients only if the industry ceases to pursue "safe" incremental innovation, reengages in high-risk discovery research, and adpots collaborative innovation models that allow sharing of knowledge and costs among collaborators.

View the full article.

World Health Organization with the Stop TB Partnership. The Stop TB Strategy: Building on and enhancing DOTS to meet the TB-related Millennium Development Goals. 2006.

The major progress in global tuberculosis (TB) control seen in the past decade has been due in large part to the development and widespread implementation of the DOTS strategy, especially in countries with a high burden of TB. Building on current achievements, and in accordance with the 2005 World Health Assembly resolution on sustainable financing for TB control, the major task for the next decade is to achieve the Millennium Development Goal (MDG) and related Stop TB Partnership targets for TB control, which have been set for 2015. As with the DOTS strategy, some of the targets relate to TB diagnosis and cure; others are concerned with epidemiological impact, including reversing incidence and halving the 1990 level of TB prevalence and death rates. Meeting these targets requires a coherent strategy that is capable of sustaining existing achievements and addressing remaining constraints and challenges more effectively. This document defines such a strategy – the Stop TB Strategy. (excerpted from Preface by Mario Raviglione)

Read a one-page summary.

Read the full report.

Visit the WHO site for more about efforts to stop TB.